Volume 3, Issue 1 (Winter 2022)
J Vessel Circ 2022, 3(1): 7-16 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tatarpoor P, Sheikh Gholami S, Rezapour A, Rahbar A. The Outcomes and Cost of Therapeutic Interventions in Cardiovascular Patients: A Case Study for Application in Cost-Effectiveness Studies. J Vessel Circ 2022; 3 (1) :7-16
URL: http://jvessels.muq.ac.ir/article-1-201-en.html
URL: http://jvessels.muq.ac.ir/article-1-201-en.html
1- School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran
2- Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
3- Department of Public Health, School of Health, Qom University of Medical Sciences, Qom, Iran.
2- Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
3- Department of Public Health, School of Health, Qom University of Medical Sciences, Qom, Iran.
Abstract: (835 Views)
Background and Aim: Currently, cardiovascular diseases, including coronary heart disease, are one of the leading causes of death in humans worldwide. In the Eastern Mediterranean and the Middle East, including our country, cardiovascular diseases are major health and social problems, the size of which is rapidly increasing. Due to the growth of medical technologies, population growth, and lifestyle changes, studying the consequences and costs of healthcare is a critical issue in the health system. This study aimed to evaluate the outcomes and costs of revascularization interventions (angioplasty and surgery) and medical therapy in cardiovascular patients.
Materials and Methods: This is a descriptive applied study. Patients after angiography and diagnosis according to the available guidelines were treated by one of the three methods of angioplasty (644 patients), surgery (366 patients), and medical therapy (805 patients) in a public hospital in Iran. The data collection tool includes a questionnaire to collect demographic, clinical and cost information of patients. Quantitative variables, such as age and costs, in the form of Mean±SD, and qualitative variables, in the form of percentage and frequency, were presented and compared. The final result of the costs was in the form of average direct costs in coronary artery surgery, angioplasty, and drug therapy were extracted and reported using SPSS software. The considered complications are the occurrence of death, heart attack, and stroke as safety outcome (SO) and performing revascularization (angioplasty or coronary bypass operation) and disease progression confirmed by re-angiography as effectiveness outcome (EO).
Results: Out of 1815 patients studied, 790 patients (43.5%) experienced at least one of the following outcomes, 101 deaths (5.6%), 170 heart attacks (9.4%), 38 strokes (2.1%), 201 angioplasty (11%), 116 cases of coronary artery bypass grafting (6.4%), and 164 cases of new coronary artery involvement (9%). The frequencies of complications in the treatment subgroups were as follows: in the medical therapy group, 101 deaths (12.5%), 140 cases of SO (17.3%), and 223 cases of EO (27.7%); in the angioplasty group, 97 deaths (15%), 92 cases of SO (14.3%), and 167 cases of EO (25.9%), and in the surgical group, 38 cases of death (10.4%), 77 cases of SO (21%), and 91 cases of EO (24.9%). The probability of medical therapy for angioplasty and surgery during 8 years was 10.2% and 9.8%, respectively. Also, the probability of angioplasty for re-angioplasty and surgery was 12.3% and 4.3%, respectively, and the probability of surgery for re-angioplasty and surgery was 10.9% and 2.5%, respectively. The average cost of direct treatment (hospitalization) in the group of percutaneous coronary intervention was 148 million rials; in the group of the coronary artery bypass graft, it was 215 million rials, and in the group of medical therapy, it was 42 million rials.
Conclusion: Patients with coronary artery disease have a more than 43% chance of developing cardiovascular complications within 8 years after diagnosis. Patients treated with angioplasty had fewer complications. Also, surgical treatment costs are higher than the other two treatments. Cardiovascular diseases are a group of diseases with high costs and heavy economic burdens on society and the family. Health policymakers can limit the costs and outcomes of the disease by using resources efficiently and effectively by expanding screening and self-care programs.
Materials and Methods: This is a descriptive applied study. Patients after angiography and diagnosis according to the available guidelines were treated by one of the three methods of angioplasty (644 patients), surgery (366 patients), and medical therapy (805 patients) in a public hospital in Iran. The data collection tool includes a questionnaire to collect demographic, clinical and cost information of patients. Quantitative variables, such as age and costs, in the form of Mean±SD, and qualitative variables, in the form of percentage and frequency, were presented and compared. The final result of the costs was in the form of average direct costs in coronary artery surgery, angioplasty, and drug therapy were extracted and reported using SPSS software. The considered complications are the occurrence of death, heart attack, and stroke as safety outcome (SO) and performing revascularization (angioplasty or coronary bypass operation) and disease progression confirmed by re-angiography as effectiveness outcome (EO).
Results: Out of 1815 patients studied, 790 patients (43.5%) experienced at least one of the following outcomes, 101 deaths (5.6%), 170 heart attacks (9.4%), 38 strokes (2.1%), 201 angioplasty (11%), 116 cases of coronary artery bypass grafting (6.4%), and 164 cases of new coronary artery involvement (9%). The frequencies of complications in the treatment subgroups were as follows: in the medical therapy group, 101 deaths (12.5%), 140 cases of SO (17.3%), and 223 cases of EO (27.7%); in the angioplasty group, 97 deaths (15%), 92 cases of SO (14.3%), and 167 cases of EO (25.9%), and in the surgical group, 38 cases of death (10.4%), 77 cases of SO (21%), and 91 cases of EO (24.9%). The probability of medical therapy for angioplasty and surgery during 8 years was 10.2% and 9.8%, respectively. Also, the probability of angioplasty for re-angioplasty and surgery was 12.3% and 4.3%, respectively, and the probability of surgery for re-angioplasty and surgery was 10.9% and 2.5%, respectively. The average cost of direct treatment (hospitalization) in the group of percutaneous coronary intervention was 148 million rials; in the group of the coronary artery bypass graft, it was 215 million rials, and in the group of medical therapy, it was 42 million rials.
Conclusion: Patients with coronary artery disease have a more than 43% chance of developing cardiovascular complications within 8 years after diagnosis. Patients treated with angioplasty had fewer complications. Also, surgical treatment costs are higher than the other two treatments. Cardiovascular diseases are a group of diseases with high costs and heavy economic burdens on society and the family. Health policymakers can limit the costs and outcomes of the disease by using resources efficiently and effectively by expanding screening and self-care programs.
Type of Study: Research |
Subject:
cardiovascular diseases
Received: 2022/02/1 | Accepted: 2022/04/9 | Published: 2022/07/1
Received: 2022/02/1 | Accepted: 2022/04/9 | Published: 2022/07/1
References
1. GBD 2019 diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019. Lancet. 2020; 396(10258):1204-22. [DOI:10.1016/S0140-6736(20)30925-9] [PMID] [PMCID] [DOI:10.1016/S0140-6736(20)30925-9]
2. Sheikhgholami S, Ebadifardazar F, Rezapoor A, Tajdini M, Salarifar M. Social and economic costs and health-related quality of life in patients with acute coronary syndrome. Value Health Reg Issues. 2021; 24:123-9. [DOI:10.1016/j.vhri.2020.11.002] [PMID] [DOI:10.1016/j.vhri.2020.11.002]
3. Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, AlHabib KF, et al., Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: The prospective urban rural epidemiologic (PURE) study. Lancet Global Health. 2019; 7(6):e748-60. [DOI:10.1016/S2214-109X(19)30045-2] [PMID] [DOI:10.1016/S2214-109X(19)30045-2]
4. Engelgau M, Rosenhouse S, El-Saharty S, Mahal A. The economic effect of noncommunicable diseases on households and nations: A review of existing evidence. J Health Commun. 2011; 16 Suppl 2:75-81. [DOI:10.1080/10810730.2011.601394] [PMID] [DOI:10.1080/10810730.2011.601394]
5. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al., Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. J Am Coll Cardiol. 2020; 76(25):2982-3021. [DOI:10.1016/j.jacc.2020.11.010] [PMID] [PMCID] [DOI:10.1016/j.jacc.2020.11.010]
6. Naghavi M, Shahraz S, Sepanlou SG, Dicker D, Naghavi P, Pourmalek F, et al. Health transition in Iran toward chronic diseases based on results of global burden of disease 2010. Arch Iran Med. 2014; 17(5):321-35. [PMID]
7. Shams-Beyranvand M, Farzadfar F, Naderimagham S, Tirani M, Maracy MR. Estimation of burden of ischemic heart diseases in Isfahan, Iran, 2014: Using incompleteness and misclassification adjustment models. J Diabetes Metab Disord. 2017; 16:12. [DOI:10.1186/s40200-017-0294-6] [PMID] [PMCID] [DOI:10.1186/s40200-017-0294-6]
8. Seo H, Yoon SJ, Yoon J, Kim D, Gong Y, Kim AR, et al. Recent trends in economic burden of acute myocardial infarction in South Korea. Plos One. 2015; 10(2):e0117446. [DOI:10.1371/journal.pone.0117446] [PMID] [PMCID] [DOI:10.1371/journal.pone.0117446]
9. Zheng H, Ehrlich F, Amin J. Economic evaluation of the direct healthcare cost savings resulting from the use of walking interventions to prevent coronary heart disease in Australia. Int J Health Care Finance Econ. 2010; 10(2):187-201. [DOI:10.1007/s10754-009-9074-2] [PMID] [DOI:10.1007/s10754-009-9074-2]
10. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al., Forecasting the future of cardiovascular disease in the United States: A policy statement from the American heart association. Circulation. 2011; 123(8):933-44. [DOI:10.1161/CIR.0b013e31820a55f5] [PMID] [DOI:10.1161/CIR.0b013e31820a55f5]
11. Pakdaman M, Gravandi S, Askari R, Shafii M, Khaleghi Muri M, Bahariniya S, et al. Estimation of the economic burden of cardiovascular diseases in selected hospitals of Yazd in 2018. Qom Univ Med Sci J. 2020; 14(7):58-68. [DOI:10.29252/qums.14.7.58] [DOI:10.29252/qums.14.7.58]
12. Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: Final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014; 35(40):2821-30. [DOI:10.1093/eurheartj/ehu213] [PMID] [DOI:10.1093/eurheartj/ehu213]
13. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009; 360(10):961-72. [DOI:10.1056/NEJMoa0804626] [PMID] [DOI:10.1056/NEJMoa0804626]
14. Abdallah MS, Wang K, Magnuson EA, Spertus JA, Farkouh ME, Fuster V, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: A randomized clinical trial. JAMA, 2013; 310(15):1581-90. [DOI:10.1001/jama.2013.279208] [PMID] [PMCID] [DOI:10.1001/jama.2013.279208]
15. Caggegi A, Capodanno D, Capranzano P, Chisari A, Ministeri M, Mangiameli A, et al. Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the customize registry). Am J Cardiol. 2011; 108(3):355-9. [DOI:10.1016/j.amjcard.2011.03.050] [PMID] [DOI:10.1016/j.amjcard.2011.03.050]
16. Chang M, Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, et al. Comparison of outcome of coronary artery bypass grafting versus drug-eluting stent implantation for non-ST-elevation acute coronary syndrome. Am J Cardiol. 2017; 120(3):380-6. [DOI:10.1016/j.amjcard.2017.04.038] [PMID] [DOI:10.1016/j.amjcard.2017.04.038]
17. Garg A, Rao SV, Agrawal S, Theodoropoulos K, Mennuni M, Sharma A, et al. Meta-analysis of randomized controlled trials of percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease. Am J Cardiol. 2017; 119(12):1942-8. [DOI:10.1016/j.amjcard.2017.03.019] [PMID] [DOI:10.1016/j.amjcard.2017.03.019]
18. Rahouma M, Abouarab A, Di Franco A, Leonard JR, Lau C, Kamel M, et al. Percutaneous coronary intervention versus coronary bypass surgery for unprotected left main disease: A meta-analysis of randomized controlled trials. Ann Cardiothorac Surg. 2018; 7(4):454-62. [DOI:10.21037/acs.2018.06.05] [PMID] [PMCID] [DOI:10.21037/acs.2018.06.05]
19. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The task force on the management of st-segment elevation acute myocardial infarction of the European society of cardiology. Eur Heart J. 2008; 29(23):2909-45. [DOI:10.1093/eurheartj/ehn416] [PMID] [DOI:10.1093/eurheartj/ehn416]
20. Task force for diagnosis and treatment of non-st-segment elevation acute coronary syndromes of European society of cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007; 28(13):1598-660. [DOI:10.1093/eurheartj/ehm161] [PMID] [DOI:10.1093/eurheartj/ehm161]
21. Gholami SS, Azar FEF, Rezapour A, Tajdini M. Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: A systematic review. Heart Fail Rev. 2019; 24(6):967-5. [DOI:10.1007/s10741-019-09811-3] [PMID] [DOI:10.1007/s10741-019-09811-3]
22. Wijeysundera HC, Bennell MC, Qiu F, Ko DT, Tu JV, Wijeysundera DN, et al. Comparative-effectiveness of revascularization versus routine medical therapy for stable ischemic heart disease: A population-based study. J Gen Intern Med. 2014; 29(7):1031-9. [DOI:10.1007/s11606-014-2813-1] [PMID] [PMCID] [DOI:10.1007/s11606-014-2813-1]
23. Brandão SMG, Rezende PC, Rocca HB, Ju YT, de Lima ACP, Takiuti ME, et al. Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. Cost Eff Resour Alloc. 2018; 16:55. [DOI:10.1186/s12962-018-0158-z] [PMID] [PMCID] [DOI:10.1186/s12962-018-0158-z]
24. Ladwiniec A, Allgar V, Thackray S, Alamgir F, Hoye A. Medical therapy, percutaneous coronary intervention and prognosis in patients with chronic total occlusions. Heart. 2015; 101(23):1907-14. [DOI:10.1136/heartjnl-2015-308181] [PMID] [DOI:10.1136/heartjnl-2015-308181]
25. Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med. 2009; 122(2):152-61. [DOI:10.1016/j.amjmed.2008.07.027] [PMID] [DOI:10.1016/j.amjmed.2008.07.027]
26. Rueda P, Richart A, Récalde A, Gasse P, Vilar J, Guérin C, et al. Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions. Circulation. 2012; 126(15):1882-95. [DOI:10.1161/CIRCULATIONAHA.112.113290] [PMID] [PMCID] [DOI:10.1161/CIRCULATIONAHA.112.113290]
27. Fanari Z, Weiss SA, Zhang W, Sonnad SS, Weintraub WS. Comparison of percutaneous coronary intervention with drug eluting stents versus coronary artery bypass grafting in patients with multivessel coronary artery disease: Meta-analysis of six randomized controlled trials. Cardiovasc Revasc Med. 2015; 16(2):70-7. [DOI:10.1016/j.carrev.2015.01.002] [PMID] [PMCID] [DOI:10.1016/j.carrev.2015.01.002]
28. Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015; 372(13):1204-12. [DOI:10.1056/NEJMoa1415447] [PMID] [DOI:10.1056/NEJMoa1415447]
29. Parasca CA, Head SJ, Milojevic M, Mack MJ, Serruys PW, Morice MC, et al. Incidence, characteristics, predictors, and outcomes of repeat revascularization after percutaneous coronary intervention and coronary artery bypass grafting: The syntax trial at 5 years. JACC Cardiovasc Interv. 2016; 9(24):2493-507. [DOI:10.1016/j.jcin.2016.09.044] [PMID] [DOI:10.1016/j.jcin.2016.09.044]
30. Alam M, Virani SS, Shahzad SA, Siddiqui S, Siddiqui KH, Mumtaz SA, et al. Comparison by meta-analysis of percutaneous coronary intervention versus coronary artery bypass grafting in patients with a mean age of ≥70 years. Am J Cardiol. 2013; 112(5):615-22. [DOI:10.1016/j.amjcard.2013.04.034] [PMID] [DOI:10.1016/j.amjcard.2013.04.034]
31. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, et al. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008; 1(1):12-20. [DOI:10.1161/CIRCOUTCOMES.108.798462] [PMID] [DOI:10.1161/CIRCOUTCOMES.108.798462]
32. Caruba T, Katsahian S, Schramm C, Charles Nelson A, Durieux P, Bégué D, et al. Treatment for stable coronary artery disease: A network meta-analysis of cost-effectiveness studies. Plos One. 2014; 9(6):e98371. [DOI:10.1371/journal.pone.0098371] [PMID] [PMCID] [DOI:10.1371/journal.pone.0098371]
33. Claude J, Schindler C, Kuster GM, Schwenkglenks M, Szucs T, Buser P, et al. Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease: Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J. 2004; 25(24):2195-203. [DOI:10.1016/j.ehj.2004.09.013] [PMID] [DOI:10.1016/j.ehj.2004.09.013]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2717-0357
Email: jvessels[at]muq.ac.ir
j.vessels.circul[at]gmail.com
